Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,104,043 shares of the biopharmaceutical company's stock after selling 33,400 shares during the period. New York State Teachers Retirement System owned 0.09% of Gilead Sciences worth $123,708,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in GILD. Brighton Jones LLC raised its stake in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Gilead Sciences in the fourth quarter worth $35,000. Proficio Capital Partners LLC purchased a new position in Gilead Sciences in the fourth quarter worth $339,000. Parkside Financial Bank & Trust increased its position in shares of Gilead Sciences by 7.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,007 shares of the biopharmaceutical company's stock worth $278,000 after purchasing an additional 217 shares in the last quarter. Finally, Flputnam Investment Management Co. lifted its holdings in shares of Gilead Sciences by 9.3% during the 4th quarter. Flputnam Investment Management Co. now owns 5,772 shares of the biopharmaceutical company's stock valued at $533,000 after purchasing an additional 490 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer directly owned 620,268 shares in the company, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the sale, the chief financial officer directly owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,500 shares of company stock worth $5,236,245 over the last three months. Insiders own 0.27% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on GILD. Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Bank of America increased their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Price Performance

GILD stock traded up $0.34 during trading on Tuesday, hitting $111.21. The stock had a trading volume of 1,801,258 shares, compared to its average volume of 7,655,779. Gilead Sciences, Inc. has a twelve month low of $66.01 and a twelve month high of $119.96. The company's 50-day moving average price is $106.53 and its two-hundred day moving average price is $103.56. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The stock has a market capitalization of $138.34 billion, a P/E ratio of 23.38, a PEG ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period in the previous year, the company posted ($1.32) earnings per share. The business's revenue was down .3% on a year-over-year basis. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.